In patients with progressive multiple sclerosis (MS), serum biomarkers may help predict future disease activity and progression, according to researchers in Boston, USA.
Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) are markers of neurodegeneration and astrocytic activation, which are hallmarks of progression MS, the researchers noted. Therefore, they analyzed whether sNfL and sGFAP could help stratify patients with progressive MS based on future disease activity and the risk of progression.